AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15070001 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional structured interview questions addressing awareness of various capacities
Number of subjects: 64
Study 15070001 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre- and post-performance estimates of ability on tasks
Number of subjects: 64
Study 15070001 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimates of current ability on bilateral and unilateral tasks
Number of subjects: 64
Study 15070001 — intervention group
Group type: EXPERIMENTAL
Intervention: Explanations of bimanual task performance
Number of subjects: 64
Study 15070001 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dissociation analysis
Number of subjects: 64
Study 11768548 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (pharmacology plus expectancy)
Number of subjects: 48
Study 11768548 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (expectancy only)
Number of subjects: 48
Study 11768548 — intervention group
Group type: COMPARATOR
Intervention: Control (no pharmacology and no expectancy)
Number of subjects: 48
Study 9271767 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) at 40 to 60% of maximum voluntary contraction (n = 12)
Number of subjects: 26
Study 9271767 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 26
Study 9271767 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT)
Number of subjects: 26
Study 8140874 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 90
Study 8140874 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol for induction followed by isoflurane anaesthesia
Number of subjects: 90
Study 8140874 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental for induction followed by isoflurane anaesthesia
Number of subjects: 90
Study 8140874 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study 8140874 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 90
Study 3048784 — intervention group
Group type: EXPERIMENTAL
Intervention: New immunoinhibition method for pancreatic isoamylase determination
Number of subjects: 0
Study 30946207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks; increased to 150 mg at Week 12 if LDL-C ≥ 70 mg/dL at Week 8)
Number of subjects: 116
Study 30946207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 30946207 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 116
Study 30946207 — intervention group
Group type: COMPARATOR
Intervention: Alirocumab and Placebo
Number of subjects: 116
Study 28257919 — intervention group
Group type: EXPERIMENTAL
Intervention: MoodSwings 2.0 online intervention for bipolar disorder
Number of subjects: 0
Study 28257919 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 0
Study 27651331 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide plus dapagliflozin
Number of subjects: 695
Study 27651331 — intervention group
Group type: COMPARATOR
Intervention: Exenatide alone
Number of subjects: 695
Study 27651331 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin alone
Number of subjects: 695
Study 23330822 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine + naphazoline
Number of subjects: 156
Study 23330822 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 156
Study 23330822 — intervention group
Group type: EXPERIMENTAL
Intervention: topical diclofenac + tobramycin
Number of subjects: 156
Study 23330822 — intervention group
Group type: COMPARATOR
Intervention: topical tobramycin
Number of subjects: 156
Study 23330822 — intervention group
Group type: EXPERIMENTAL
Intervention: topical naphazoline
Number of subjects: 156
Study 21105974 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% natamycin (group A)
Number of subjects: 30
Study 21105974 — intervention group
Group type: COMPARATOR
Intervention: 1% voriconazole (group B)
Number of subjects: 30
Study 19050973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy followed by axillary clearance if sentinel node positive or not detected (SNBM)
Number of subjects: 1088
Study 19050973 — intervention group
Group type: COMPARATOR
Intervention: Routine axillary clearance (RAC)
Number of subjects: 1088
Study 19050973 — intervention group
Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (SNB)
Number of subjects: 1088
Study 16908618 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery
Number of subjects: 18
Study 16908618 — intervention group
Group type: COMPARATOR
Intervention: Conventional thoracostomy drainage
Number of subjects: 18
Study 15017615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib (800 mg every day)
Number of subjects: 24
Study 15017615 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 24
Study 15017615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11349930 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable contact lenses
Number of subjects: 116
Study 9230275 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily supplementation of 0.7 mg free folic acid in cereal for 2 months followed by 2.0 mg free folic acid via a tablet for 4 months
Number of subjects: 64
Study 9230275 — intervention group
Group type: COMPARATOR
Intervention: Normal levels of folate, vitamin B12, and homocysteine
Number of subjects: 64
Study 9230275 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal folate and vitamin B12, but homocysteine levels >10 micromol/l
Number of subjects: 64
Study 9230275 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with one or more abnormal blood values for folate, vitamin B12 or homocysteine
Number of subjects: 64
Study 8197064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy program for behaviorally disordered mentally handicapped patients
Number of subjects: 0
Study 3372923 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied kinesiology assessment of nutrient status
Number of subjects: 11
Study 3372923 — intervention group
Group type: COMPARATOR
Intervention: Applied kinesiology assessment compared to standard laboratory tests
Number of subjects: 11
Study 3372923 — intervention group
Group type: COMPARATOR
Intervention: Applied kinesiology assessment compared to computerized isometric muscle testing
Number of subjects: 11
Study 3372923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient supplementation (thiamin, zinc, vitamin A, ascorbic acid)
Number of subjects: 11
Study 3372923 — intervention group
Group type: COMPARATOR
Intervention: Placebo (pectin and sucrose)
Number of subjects: 11
Study 29433545 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation treatment using the GRADIOR programme
Number of subjects: 400
Study 29433545 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention (PSS) using the ehcoBUTLER platform
Number of subjects: 400
Study 29433545 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment consisting of GRADIOR and ehcoBUTLER
Number of subjects: 400
Study 29433545 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 400
Study 27756783 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of 7 lipid species to a base model (14 traditional risk factors and medications)
Number of subjects: 3779
Study 27756783 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of 4 lipid species into the base model
Number of subjects: 3779
Study 24831037 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telecommunication-based reminders (daily messages via text or voice)
Number of subjects: 70
Study 24831037 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study 22935508 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment
Number of subjects: 30
Study 22935508 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ulcers
Number of subjects: 30
Study 22935508 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 or more oral ulcers during 6 months
Number of subjects: 30
Study 22935508 — intervention group
Group type: EXPERIMENTAL
Intervention: Genital ulcers, follicular lesions, and erythema nodosum
Number of subjects: 30
Study 19243993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - Large to small muscle group exercises
Number of subjects: 0
Study 19243993 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - Small to large muscle group exercises
Number of subjects: 0
Study 19243993 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No exercise
Number of subjects: 0
Study 19243993 — intervention group
Group type: EXPERIMENTAL
Intervention: Small muscle group exercises (comparison between G1 and G2)
Number of subjects: 0
Study 18174609 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose regimen (HD): two cycles of E(90)C(600) every 2 weeks followed by two cycles of E(90)C(3000)Thiotepa(400) every 3 weeks.
Number of subjects: 236
Study 18174609 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense conventional chemotherapy (DD): four cycles of E(90)C(600) followed by three cycles of C(600)M(40)F(600) every 2 weeks.
Number of subjects: 236
Study 16900444 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls data collection over a 12-month period
Number of subjects: 293
Study 16900444 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls occurring outside the home during leisure activities
Number of subjects: 293
Study 16900444 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender influence on fall characteristics
Number of subjects: 293
Study 12565982 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 164
Study 12565982 — intervention group
Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 164
Study 11103234 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0
Study 11103234 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemoimmunotherapy
Number of subjects: 0
Study 11103234 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 8839500 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard diet with 10 mg total carotenoids/d for two cycles
Number of subjects: 12
Study 8098281 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine (3 x 100 mg/day p.o.)
Number of subjects: 18
Study 8098281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2441736 — intervention group
Group type: EXPERIMENTAL
Intervention: PVB chemotherapy (cisplatin, vinblastine, and bleomycin)
Number of subjects: 47
Study 2441736 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 47
Study 31345049 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding training during prenatal and postnatal periods
Number of subjects: 120
Study 29940166 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2.REP1 (0.1 mL containing 10^11 genome particles)
Number of subjects: 6
Study 27777234 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 340
Study 27777234 — intervention group
Group type: COMPARATOR
Intervention: Coronary Angiography
Number of subjects: 340
Study 25455617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power brush with a novel brush head
Number of subjects: 94
Study 25455617 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 94
Study 23756247 — intervention group
Group type: EXPERIMENTAL
Intervention: Supraclavicular approach (SC)
Number of subjects: 98
Study 23756247 — intervention group
Group type: COMPARATOR
Intervention: Infraclavicular approach (IC)
Number of subjects: 98
Study 23756247 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 98
Study 21702233 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h)
Number of subjects: 20211
Study 21702233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20211
Study 18988471 — intervention group
Group type: EXPERIMENTAL
Intervention: Injector
Number of subjects: 46
Study 18988471 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 46
Study 18988471 — intervention group
Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 46
Study 15730542 — intervention group
Group type: COMPARATOR
Intervention: DVP delayed-release/sprinkle
Number of subjects: 31
Study 15730542 — intervention group
Group type: COMPARATOR
Intervention: DVP sprinkle formulation
Number of subjects: 31
Study 15730542 — intervention group
Group type: EXPERIMENTAL
Intervention: DVP extended-release tablets
Number of subjects: 31
Study 12538173 — intervention group
Group type: EXPERIMENTAL
Intervention: Allon thermoregulation (AT), n = 30
Number of subjects: 60
Study 12538173 — intervention group
Group type: COMPARATOR
Intervention: Routine thermal care (RTC), n = 30
Number of subjects: 60
Study 11085961 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained (TR) group underwent a residential exercise program at 85% of maximum heart rate, consisting of 2 daily sessions 6 times a week for 2 weeks.
Number of subjects: 97
Study 11085961 — intervention group
Group type: COMPARATOR
Intervention: Untrained (UTR) group, control group, no intervention.
Number of subjects: 97
Study 8784318 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y esophagojejunostomy
Number of subjects: 27
Study 8784318 — intervention group
Group type: COMPARATOR
Intervention: Hunt-Rodino-Lawrence pouch (HRL)
Number of subjects: 27
Study 1623657 — intervention group
Group type: EXPERIMENTAL
Intervention: diltiazem CD (n = 61)
Number of subjects: 127
Study 1623657 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 66)
Number of subjects: 127
Study 3926322 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg each, 3 tablets)
Number of subjects: 114
Study 3926322 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine combination (2 mg ergotamine tartrate, 91.5 mg caffeine, 50 mg cyclizine chlorhydrate, 1 tablet)
Number of subjects: 114
Study 3926322 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 114
Study 3926322 — intervention group
Group type: COMPARATOR
Intervention: Ergotamine combination
Number of subjects: 114
Study 31079072 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n=45)
Number of subjects: 90
Study 31079072 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=45)
Number of subjects: 90
Study 29859789 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated whole-breast radiation therapy (RT)
Number of subjects: 348
Study 26849996 — intervention group
Group type: EXPERIMENTAL
Intervention: I Move; a web‐based PA intervention based on SDT and MI
Number of subjects: 0
Study 26849996 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Plus; a traditional web‐based PA intervention
Number of subjects: 0
Study 26849996 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 0
Study 24832463 — intervention group
Group type: EXPERIMENTAL
Intervention: LOLA
Number of subjects: 40
Study 24832463 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 22266605 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary irradiation stent
Number of subjects: 23
Study 22266605 — intervention group
Group type: COMPARATOR
Intervention: Conventional biliary stent
Number of subjects: 23
Study 19731311 — intervention group
Group type: EXPERIMENTAL
Intervention: Trocar guided transvaginal mesh
Number of subjects: 50
Study 19731311 — intervention group
Group type: COMPARATOR
Intervention: Colporraphy
Number of subjects: 50
Study 18608057 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based HIV behavioral intervention
Number of subjects: 280
Study 18608057 — intervention group
Group type: COMPARATOR
Intervention: Control group (educational materials)
Number of subjects: 280
Study 16043734 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch G2 Biographer (GW2B)
Number of subjects: 163
Study 11978675 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic index (LGI) diet
Number of subjects: 11
Study 10071170 — intervention group
Group type: EXPERIMENTAL
Intervention: Efamol Marine
Number of subjects: 50
Study 10071170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 7751891 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 491
Study 7751891 — intervention group
Group type: EXPERIMENTAL
Intervention: VATH (vinblastine, doxorubicin, thiotepa, and halotestin)
Number of subjects: 491
Study 7751891 — intervention group
Group type: EXPERIMENTAL
Intervention: VATH alternating with CMFVP (cyclophosphamide, methotrexate, fluorouracil, vincristine, and prednisone)
Number of subjects: 491
Study 7751891 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 491
Study 2345394 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 types of epidural catheters
Number of subjects: 1415
Study 2345394 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard catheter against resistance to insertion
Number of subjects: 1415
Study 2345394 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft catheter
Number of subjects: 1415
Study 574352 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isolate-based formula supplemented with L-methionine
Number of subjects: 19
Study 574352 — intervention group
Group type: COMPARATOR
Intervention: Soy isolate-based formula unsupplemented with methionine
Number of subjects: 19
Study 31038991 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 50
Study 31038991 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical instrumentation (CSI)
Number of subjects: 50
Study 28399873 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional gait‐oriented mental practice combined with gait training (40 min, 3 times/week, for 4 weeks)
Number of subjects: 15
Study 28399873 — intervention group
Group type: COMPARATOR
Intervention: Non-motor task mental practice
Number of subjects: 15
Study 25836922 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3
Number of subjects: 66
Study 25836922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 24053549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Matters programme
Number of subjects: 268
Study 24053549 — intervention group
Group type: COMPARATOR
Intervention: Routine access to health and social care (Control)
Number of subjects: 268
Study 21834112 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalist‐ACE service
Number of subjects: 217
Study 19307271 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat prenatal corticosteroid treatment (weekly betamethasone)
Number of subjects: 145
Study 19307271 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 145
Study 16680099 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT)
Number of subjects: 81
Study 16680099 — intervention group
Group type: COMPARATOR
Intervention: Slit-lamp indirect ophthalmoscopy by specialists
Number of subjects: 81
Study 16680099 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OCT and specialists
Number of subjects: 81
Study 15053915 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental bonding system (Exp) with 10% ascorbic acid and 5% ferric chloride; conditioned with phosphoric acid, NaOCl, and Exp; bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0
Study 15053915 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia Fluoro Cement with AD gel (AD/Panavia); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0
Study 15053915 — intervention group
Group type: COMPARATOR
Intervention: Super‐Bond C&B (10‐3); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0
Study 15053915 — intervention group
Group type: COMPARATOR
Intervention: Panavia Fluoro Cement (Panavia); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0
Study 15053915 — intervention group
Group type: COMPARATOR
Intervention: All‐Bond 2 system (All‐Bond 2); bonded with 4‐META/MMA‐TBB resin.
Number of subjects: 0
Study 11829219 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump coronary artery bypass grafting (OPCAB)
Number of subjects: 157
Study 11829219 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 157
Study 9725481 — intervention group
Group type: EXPERIMENTAL
Intervention: Manidipine 20 mg tablet administered after a standardized breakfast
Number of subjects: 12
Study 7848346 — intervention group
Group type: EXPERIMENTAL
Intervention: Vita‐Gerin‐Geistlich (1 capsule/day)
Number of subjects: 43
Study 7848346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 3178294 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal breathing during 30-min exposure to approximately 0.4 ppm O3
Number of subjects: 0
Study 3178294 — intervention group
Group type: COMPARATOR
Intervention: Oral breathing during 30-min exposure to approximately 0.4 ppm O3
Number of subjects: 0
Study 167583 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin
Number of subjects: 120
Study 167583 — intervention group
Group type: COMPARATOR
Intervention: Neomycin and Polymyxin B combination
Number of subjects: 120
Study 31289351 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant fluorouracil-based chemotherapy
Number of subjects: 397
Study 31289351 — intervention group
Group type: COMPARATOR
Intervention: Surgery-only
Number of subjects: 397
Study 28296257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg in 250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Number of subjects: 133
Study 28296257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml saline) administered in 2 courses at weeks 0, 2, 24, and 26.
Number of subjects: 133
Study 28296257 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 133
Study 28296257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 26388067 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical removal of impacted lower third molars in overweight patients
Number of subjects: 560